In the most recent edition of the Life Science Leader magazine, the value of biotech partnerships in China was put under a spotlight.
The two pager describes the importance the China biotech market is gaining every year, with an increasing number of deals made between companies internationally.
One of the main examples used in the article is the deal between the Belgian company Octimet Oncology and the Chinese Allist Pharmaceuticals, a deal closed and supported by Agio Capital. We are very proud our impact is making a difference in the industry!
Want to read the full article? Click here.
